» Articles » PMID: 32789000

Variable Expression and Silencing of CRISPR-Cas9 Targeted Transgenes Identifies the Locus As Not an Entirely Safe Harbour

Overview
Journal F1000Res
Date 2020 Aug 18
PMID 32789000
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Diseases such as hypertrophic cardiomyopathy (HCM) can lead to severe outcomes including sudden death. The generation of human induced pluripotent stem cell (hiPSC) reporter lines can be useful for disease modelling and drug screening by providing physiologically relevant models of disease. The locus is cited as a safe harbour that is permissive for stable transgene expression, and hence is favoured for creating gene targeted reporter lines. : We generated hiPSC reporters using a plasmid-based CRISPR/Cas9 nickase strategy. The first intron of , the locus, was targeted with constructs expressing a genetically encoded calcium indicator (R-GECO1.0) or HOXA9-T2A-mScarlet reporter under the control of a pCAG or inducible pTRE promoter, respectively. Transgene expression was compared between clones before, during and/or after directed differentiation to mesodermal lineages. : Successful targeting to was confirmed by PCR and sequencing. Of 24 hiPSC clones targeted with pCAG-R-GECO1.0, only 20 expressed the transgene and in these, the percentage of positive cells ranged from 0% to 99.5%. Differentiation of a subset of clones produced cardiomyocytes, wherein the percentage of cells positive for R-GECO1.0 ranged from 2.1% to 93.1%. In the highest expressing R-GECO1.0 clones, transgene silencing occurred during cardiomyocyte differentiation causing a decrease in expression from 98.93% to 1.3%. In HOXA9-T2A-mScarlet hiPSC reporter lines directed towards mesoderm lineages, doxycycline induced a peak in transgene expression after two days but this reduced by up to ten-thousand-fold over the next 8-10 days. Nevertheless, for R-GECO1.0 lines differentiated into cardiomyocytes, transgene expression was rescued by continuous puromycin drug selection, which allowed the Ca responses associated with HCM to be investigated using single cell analysis. Targeted knock-ins to can be used to create reporter lines but variability between clones and transgene silencing requires careful attention by researchers seeking robust reporter gene expression.

Citing Articles

Optimizing approaches for targeted integration of transgenic cassettes by integrase-mediated cassette exchange in mouse and human stem cells.

Rath P, Kramer P, Biggs D, Preece C, Hortin N, Diaz R Stem Cells. 2025; 43(1).

PMID: 39777513 PMC: 11740728. DOI: 10.1093/stmcls/sxae092.


Generation and characterization of inducible KRAB-dCas9 iPSCs from primates for cross-species CRISPRi.

Edenhofer F, Termeg A, Ohnuki M, Jocher J, Kliesmete Z, Briem E iScience. 2024; 27(6):110090.

PMID: 38947524 PMC: 11214527. DOI: 10.1016/j.isci.2024.110090.


Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight.

Zhang Z, Zhang S, Wong H, Li D, Feng B BioDrugs. 2024; 38(3):369-385.

PMID: 38489061 PMC: 11055778. DOI: 10.1007/s40259-024-00654-5.


Targeted CRISPR activation is functional in engineered human pluripotent stem cells but undergoes silencing after differentiation into cardiomyocytes and endothelium.

Karbassi E, Padgett R, Bertero A, Reinecke H, Klaiman J, Yang X Cell Mol Life Sci. 2024; 81(1):95.

PMID: 38372898 PMC: 10876724. DOI: 10.1007/s00018-023-05101-2.


Computationally defined and in vitro validated putative genomic safe harbour loci for transgene expression in human cells.

Autio M, Motakis E, Perrin A, Bin Amin T, Tiang Z, Do D Elife. 2024; 13.

PMID: 38164941 PMC: 10836832. DOI: 10.7554/eLife.79592.


References
1.
Castano J, Bueno C, Jimenez-Delgado S, Roca-Ho H, Fraga M, Fernandez A . Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus. Stem Cell Res. 2017; 21:137-140. PMC: 5446316. DOI: 10.1016/j.scr.2017.04.011. View

2.
Mosqueira D, Mannhardt I, Bhagwan J, Lis-Slimak K, Katili P, Scott E . CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur Heart J. 2018; 39(43):3879-3892. PMC: 6234851. DOI: 10.1093/eurheartj/ehy249. View

3.
Papapetrou E, Schambach A . Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Mol Ther. 2016; 24(4):678-84. PMC: 4886940. DOI: 10.1038/mt.2016.38. View

4.
Kondrashov A, Duc Hoang M, Smith J, Bhagwan J, Duncan G, Mosqueira D . Simplified Footprint-Free Cas9/CRISPR Editing of Cardiac-Associated Genes in Human Pluripotent Stem Cells. Stem Cells Dev. 2018; 27(6):391-404. PMC: 5882176. DOI: 10.1089/scd.2017.0268. View

5.
Lombardo A, Genovese P, Beausejour C, Colleoni S, Lee Y, Kim K . Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007; 25(11):1298-306. DOI: 10.1038/nbt1353. View